Correlation Between LB Pharmaceuticals and Contineum Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both LB Pharmaceuticals and Contineum Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining LB Pharmaceuticals and Contineum Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between LB Pharmaceuticals Common and Contineum Therapeutics, Class, you can compare the effects of market volatilities on LB Pharmaceuticals and Contineum Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in LB Pharmaceuticals with a short position of Contineum Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of LB Pharmaceuticals and Contineum Therapeutics,.

Diversification Opportunities for LB Pharmaceuticals and Contineum Therapeutics,

-0.14
  Correlation Coefficient

Good diversification

The 3 months correlation between LBRX and Contineum is -0.14. Overlapping area represents the amount of risk that can be diversified away by holding LB Pharmaceuticals Common and Contineum Therapeutics, Class in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Contineum Therapeutics, and LB Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on LB Pharmaceuticals Common are associated (or correlated) with Contineum Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Contineum Therapeutics, has no effect on the direction of LB Pharmaceuticals i.e., LB Pharmaceuticals and Contineum Therapeutics, go up and down completely randomly.

Pair Corralation between LB Pharmaceuticals and Contineum Therapeutics,

Given the investment horizon of 90 days LB Pharmaceuticals Common is expected to under-perform the Contineum Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, LB Pharmaceuticals Common is 1.45 times less risky than Contineum Therapeutics,. The stock trades about -0.04 of its potential returns per unit of risk. The Contineum Therapeutics, Class is currently generating about 0.23 of returns per unit of risk over similar time horizon. If you would invest  580.00  in Contineum Therapeutics, Class on August 4, 2025 and sell it today you would earn a total of  521.00  from holding Contineum Therapeutics, Class or generate 89.83% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy58.46%
ValuesDaily Returns

LB Pharmaceuticals Common  vs.  Contineum Therapeutics, Class

 Performance 
       Timeline  
LB Pharmaceuticals Common 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days LB Pharmaceuticals Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest conflicting performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.
Contineum Therapeutics, 

Risk-Adjusted Performance

Solid

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Contineum Therapeutics, Class are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Contineum Therapeutics, displayed solid returns over the last few months and may actually be approaching a breakup point.

LB Pharmaceuticals and Contineum Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with LB Pharmaceuticals and Contineum Therapeutics,

The main advantage of trading using opposite LB Pharmaceuticals and Contineum Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if LB Pharmaceuticals position performs unexpectedly, Contineum Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Contineum Therapeutics, will offset losses from the drop in Contineum Therapeutics,'s long position.
The idea behind LB Pharmaceuticals Common and Contineum Therapeutics, Class pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Complementary Tools

Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Stocks Directory
Find actively traded stocks across global markets